|
|
Close Help | ||||||||||||||
 |
 |
Technology transfer
|
| Application
outputs, biotechnology spin-off companies |
||
|
Besides basic research, great
attention at the Institute is also paid to applied research and to the
possibilities of practical application of research results. At present,
the applied research at the Institute is supported (mainly in
collaboration and with financial participation of implementation
companies) by 6 grants (3x Research Centers 1M, 3x Heureka, 1x grant of
the Ministry of Industry and Trade).
Based on the results obtained at the Institute, several biotechnology spin-off companies have been established, some of which prosper well and are growing: |
||
| Top-Bio Ltd. | http://www.top-bio.cz/ |
Focused
on the development and production of reagents for DNA fragment
amplification using polymerase chain reaction. In 2004, turnover CZK 4
million. |
| EXBIO Praha Inc. |
http://www.exbio.cz/ |
Focused
on the research, development and production of monoclonal antibodies
and recombinant proteins. In 2004, turnover CZK 23 million, 20
employees. |
| Apronex Ltd. | http://www.apronex.com/ |
Focused on the development and production of recombinant proteins. In 2004, turnover CZK 0.5 million, 1 employee. |
| Cellvia Ltd. | http://www.cellvia.com/ |
Focused on
the development of small molecule-based drugs; still starting activity. |
| AppGenics Ltd. | http://www.appgenics.com/ |
Focused
on the preparation of labelled cRNA and cDNA probes for in situ
hybridization, development of new vectors with required properties,
preparation of recombinant proteins, gene cloning and arrangement and
advanced technology for preparation of transgenic and gene-defective
animal models. The company is also familiar with embryonic stem cell
technology. |
| rEcoli Ltd. |
Focused
on recombinant protein production. |
|
| Particular results that have already been implemented at the commercial basis include mainly: |
| Monoclonal antibodies for detection of
cytoskeletal proteins and some other diagnostically interesting molecules obtained in part during work on the EUREKA projects. Implementation in the EXBIO Praha Inc. company Dept. of Dr. Pavel Dráber – for details see http://www.img.cas.cz/dbc/. |
| Monoclonal antibodies against anti-tumour
cytokine TRAIL receptors, production and marketing in the spin-off company EXBIO Praha Inc. Dept. of Dr. Anděra – for details see http://www.img.cas.cz/csa/. |
| Recombinant anti-tumour cytokine TRAIL and
its highly effective derivates, production in spin-off company Apronex Ltd. Dept. of Dr. Anděra, for details see http://www.img.cas.cz/csa/, htttp://www.apronex.com. |
| Monoclonal antibodies for detection of the
HLA-G protein, crucial for successful fertilization. The diagnostic kit (first of its kind worldwide) is produced in the EXBIO Praha Inc. company Dept. of Prof. Hořejší – for details see: http://www.img.cas.cz/mi/. |
| Monoclonal antibodies for detection of 14
signalling and 78 surface molecules of human leukocytes and other
cells. Implementation in the EXBIO Praha Inc. company, which sells these products to a number of international distribution companies, e.g. Serotec, Caltag, Pharmingen, Dynal, Sanbio, Alexis, Abcam. In its time, this large series of monoclonal antibodies had become the basis for the existence of spin-off company EXBIO Praha Inc. and to date represents the main part of its range of products and turnover Dept. of Prof. Hořejší – for details see http://www.img.cas.cz/mi/, http://www.img.cas.cz/mi/Horejsi-Table.html. |
| Recombinant antigens of EBV and CMV
viruses, which are used for production of diagnostic kits for detection of these viruses in the VIDIA Ltd. company; total sale turnover based on these products is CZK 0.5 million per year Dept. of Dr. Sedláček – for details see http://www.img.cas.cz/igm/, http://www.vidia.cz. |
| webmaster | office |
